|1.||Kavallaris, Maria: 5 articles (12/2008 - 09/2002)|
|2.||Braguer, Diane: 4 articles (12/2014 - 02/2006)|
|3.||Kruczynski, Anna: 4 articles (12/2014 - 01/2002)|
|4.||Fan, Weimin: 3 articles (06/2010 - 03/2004)|
|5.||Sui, Meihua: 3 articles (06/2010 - 03/2004)|
|6.||Correia, John J: 3 articles (08/2008 - 01/2007)|
|7.||Lobert, Sharon: 3 articles (08/2008 - 01/2007)|
|8.||Hadj-Kaddour, Kamel: 2 articles (04/2015 - 02/2015)|
|9.||Cuq, Pierre: 2 articles (04/2015 - 02/2015)|
|10.||Vian, Laurence: 2 articles (04/2015 - 02/2015)|
12/01/2015 - "Vinca alkaloids are chemotherapeutic agents that have demonstrated clinical efficacy both as single agents and in combination in a broad spectrum of cancers, including MPM. "
04/01/2013 - "Clinical trials are required to prove whether Vinca alkaloids act more efficiently in cancer patients if they are applied uncoupled from cytostatic therapies. "
01/01/2015 - "Furthermore, this mechanism will be applied to develop novel vinca alkaloids with much higher cytotoxicity toward cancer cells. "
01/01/2015 - "However, because of drug resistance, toxicity, and other side effects caused from the use of VLB, new vinca alkaloids with higher cytotoxicity toward cancer cells and other good qualities need to develop. "
11/01/2013 - "Vinca alkaloids are the second-most-used class of cancer drugs and will stay among the original cancer therapies. "
|2.||Breast Neoplasms (Breast Cancer)
05/01/1986 - "Neurotoxicity and efficacy of combined vinca alkaloids in breast cancer."
05/01/1986 - "Further studies of combined vinca alkaloids are not recommended in the treatment of breast cancer."
01/01/1995 - "Vinca alkaloids are widely used in the medical treatment of breast cancer. "
02/01/1980 - "Our results suggest that vinblastine given as a continuous 5-day infusion is highly effective in the treatment of patients with advanced metastatic breast cancer, including a few whose disease was felt to be resistant to a conventional dose schedule of vinca alkaloids."
06/01/2010 - "The findings obtained from this study have provided important evidence that expression and subsequent activation of ERalpha are associated with resistance of breast cancer cells to vinca alkaloids. "
01/01/1985 - "Decreased retention of vinca alkaloids in chronic lymphatic leukemia cells from refractory patients."
07/15/1966 - "[Vinca alkaloids in the treatment of leukemia]."
06/01/2007 - "Natural product tubulin-binding agents such as the Vinca alkaloids have proven highly effective in the treatment of leukemia. "
06/10/2010 - "The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma."
10/01/1989 - "Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein."
|4.||Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
02/01/1984 - "Vinca alkaloids are useful in the treatment of idiopathic thrombocytopenic purpura, a disorder in which macrophages remove platelets sensitized with antibody. "
07/01/1984 - "Vinca alkaloids for idiopathic thrombocytopenic purpura."
06/01/1984 - "Slow infusion of vinca alkaloids in idiopathic thrombocytopenic purpura."
02/01/1984 - "Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura."
04/01/1995 - "Various drugs such as vinca alkaloids, immunoglobulins and immunosuppressant drugs have been used with variable benefits in patients with chronic idiopathic thrombocytopenic purpura (CITP) refractory to steroid therapy. "
|5.||Hematologic Neoplasms (Hematological Malignancy)
10/01/2011 - "[A retrospective analysis of neurotoxicity induced by vinca alkaloids combined with azole anti-fungal agents in hematological malignancies]."
05/01/1984 - "[A presumed transient hemolytic reaction following vinca alkaloids administration in patients with hematological malignancies]."
12/01/2011 - "Application of anthracyclines and Vinca alkaloids on the same day represents a hallmark of polychemotherapy protocols for hematopoietic malignancies. "
06/01/2008 - "Clinical activity of taxanes and first-generation vinca alkaloids in the treatment of solid tumors and hematologic malignancies, respectively, has prompted further research for novel analogs with improved clinical efficacy and safety. "
10/01/2011 - "Vinca alkaloids (VA) are some of the key anti-tumor agents for patients with hematological malignancies, and various adverse events such as paralytic ileus, peripheral neuropathy, and constipation were now recognized as adverse VA effects. "
|3.||Vinblastine (Vinblastine Sulfate)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)